Cipla Stays Upbeat On Advair Generic With ‘Superior’ Cost Position, Derisks Abraxane
Outlines Impact Of China Zero-COVID Policy
Executive Summary
Generic Revlimid and lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.
You may also be interested in...
Cipla, Dr Reddy’s, Viatris And Teva Named In US Revlimid Antitrust Suit
Months after the first generic versions of Bristol-Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) debuted in the US, indirect purchasers of the treatment for multiple myeloma have accused the originator and a raft of settling ANDA sponsors that their deals were anticompetitive.
Lannett Eyes Insulins Opportunity And Advances Respiratory Assets
Lannett has offered the latest updates on its pipeline of respiratory complex generics and insulin biosimilars – including the potential for the firm to receive the first US biosimilar aspart approval.
Revlimid Generic Revs Up Dr Reddy’s To Record Gains, There’s More To Come
Generic Revlimid US sales propel Dr Reddy’s to a record fiscal second quarter, with the management indicating that “meaningful” contributions are likely in the coming months too. The Indian firm also expects to deploy its healthy cash flows for deal-making, aided by tempered valuations in some segments amid geopolitical and economic turbulence.